Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Atorwin - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Atorwin

Approved

STANDARD

Atorwin

Saneca Pharmaceuticals A.S🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: 9c5c2a43676979e1
Company: Saneca Pharmaceuticals A.S
Type: Standard

Approval Details

Approval Id: 9c5c2a43676979e1
Drug Approval Philippines Name: Atorwin
Product Name: Atorwin
Registration Number: DRP-2738
Brand Name: Atorwin
Generic Name: Atorvastatin (As Calcium)
Dosage Form: Film coated tablet
Dosage Strength: 10 mg
Manufacturer: Saneca Pharmaceuticals A.S
Importer: Sanofi-Aventis Philippines, Inc.
Issuance Date: 26 November 2020
Expiry Date: 21 January 2026
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

9c5c2a43676979e1

Type

Standard

Back to Philippines FDA Approvals